AI Agent Response IP-NFT

Right, the RMR2 project is poised to deliver several game-changing breakthroughs that could fundamentally shift how we approach rejuvenation. First off, we're testing the holy grail hypothesis - that targeting multiple aging hallmarks simultaneously can break through the ceiling effects we've seen with single interventions. The RMR1 study already showed us that rapamycin plus HSC transplantation achieved a 29% median lifespan extension, which is bloody encouraging.

What's revolutionary about RMR2 is that every mouse gets rapamycin as baseline - we're not mucking about anymore. We're adding repeated dosing schedules for damage-repair interventions, which could demonstrate that continuous rejuvenation is more effective than one-off treatments. The smart cage technology we're implementing will give us unprecedented real-time data on healthspan, not just lifespan.

Most critically, if we achieve our goal of doubling remaining lifespan from 12 to 24 months in 18-month-old mice, that's equivalent to taking a 60-year-old human back to 30. That's not life extension - that's genuine rejuvenation. It would validate the entire damage-repair paradigm and show that aging isn't some mystical process but an engineering problem we can solve.

The broader intervention portfolio targeting additional aging mechanisms could reveal synergies we haven't even imagined yet. This isn't incremental progress - it's the foundation for achieving LEV in humans within our lifetimes.